News Releases

Insmed Incorporated (NASDAQ: INSM) announces updated results for the Company's pivotal Phase III clinical trial evaluating SomatoKine(R) (mecasermin rinfabate), a once daily insulin-like growth...

Insmed Incorporated (NASDAQ: INSM) today announced that Philip J. Young, Chief Business Officer and Executive Vice President of Commercial Operations of Insmed, will present Thursday, May 26, 2005...

Insmed Incorporated (NASDAQ: INSM) today announced that on Friday May 20, 2005, the High Court of Justice (Chancery Division, Patents Court) in London issued rulings in the patent infringement...

RICHMOND, Va., May 19, 2005 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ: INSM) today announced that Philip J. Young, Chief Business Officer and Executive Vice President of Commercial Operations...

RICHMOND, Va. & SAN FRANCISCO, Mar 17, 2005 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ: INSM) today reported that the Company has entered into an exclusive option agreement with University of...

RICHMOND, Va., May 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Insmed Incorporated (Nasdaq: INSM), a developer of pharmaceutical products for the treatment of metabolic and endocrine diseases...

RICHMOND, Va., May 5, 2005 /PRNewswire-FirstCall via COMTEX/ -- Insmed Incorporated (Nasdaq: INSM), a developer of pharmaceutical products for the treatment of metabolic and endocrine diseases...

RICHMOND, Va., April 26, 2005 /PRNewswire-FirstCall via COMTEX/ -- Insmed Incorporated (Nasdaq: INSM) today announced that it has initiated a Phase II clinical trial examining the therapeutic...

RICHMOND, Va., April 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- Insmed Incorporated (Nasdaq: INSM) today announced that it has initiated a Phase II clinical trial examining the therapeutic...

RICHMOND, Va., April 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Insmed Incorporated (Nasdaq: INSM) On April 15, 2005, the United States District Court for the Northern District of California...